Please use this identifier to cite or link to this item:
Title: Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients
Author: Cubiella, Joaquín
Vega, Pablo
Salve, María
Díaz-Ondina, Marta
Alves, Maria Teresa
Quintero, Enrique
Álvarez-Sánchez, Victoria
Fernández Bañares, Fernando
Boadas, Jaume
Campo Fernández de los Rios, Rafael
Bujanda, Luis
Clofent, Juan
Ferrandez, Ángel
Torrealba, Leyanira
Piñol Sánchez, Virgínia
Rodríguez-Alcalde, Daniel
Hernández, Vicent
Fernández-Seara, Javier
Ribes Puig, Josepa
COLONPREDICT study investigators
Keywords: Càncer colorectal
Pronòstic mèdic
Marcadors tumorals
Marcadors bioquímics
Protocols clínics
Colorectal cancer
Tumor markers
Biochemical markers
Medical protocols
Issue Date: 31-Aug-2016
Publisher: BioMed Central
Abstract: Background: risk prediction models for colorectal cancer (CRC) detection in symptomatic patients based on available biomarkers may improve CRC diagnosis. Our aim was to develop, compare with the NICE referral criteria and externally validate a CRC prediction model, COLONPREDICT, based on clinical and laboratory variables. Methods: this prospective cross-sectional study included consecutive patients with gastrointestinal symptoms referred for colonoscopy between March 2012 and September 2013 in a derivation cohort and between March 2014 and March 2015 in a validation cohort. In the derivation cohort, we assessed symptoms and the NICE referral criteria, and determined levels of faecal haemoglobin and calprotectin, blood haemoglobin, and serum carcinoembryonic antigen before performing an anorectal examination and a colonoscopy. A multivariate logistic regression analysis was used to develop the model with diagnostic accuracy with CRC detection as the main outcome. Results: we included 1572 patients in the derivation cohort and 1481 in the validation cohorts, with a 13.6 % and 9.1 % CRC prevalence respectively. The final prediction model included 11 variables: age (years) (odds ratio [OR] 1.04, 95 % confidence interval [CI] 1.02-1.06), male gender (OR 2.2, 95 % CI 1.5-3.4), faecal haemoglobin ≥20 μg/g (OR 17.0, 95 % CI 10.0-28.6), blood haemoglobin <10 g/dL (OR 4.8, 95 % CI 2.2-10.3), blood haemoglobin 10-12 g/dL (OR 1.8, 95 % CI 1.1-3.0), carcinoembryonic antigen ≥3 ng/mL (OR 4.5, 95 % CI 3.0-6.8), acetylsalicylic acid treatment (OR 0.4, 95 % CI 0.2-0.7), previous colonoscopy (OR 0.1, 95 % CI 0.06-0.2), rectal mass (OR 14.8, 95 % CI 5.3-41.0), benign anorectal lesion (OR 0.3, 95 % CI 0.2-0.4), rectal bleeding (OR 2.2, 95 % CI 1.4-3.4) and change in bowel habit (OR 1.7, 95 % CI 1.1-2.5). The area under the curve (AUC) was 0.92 (95 % CI 0.91-0.94), higher than the NICE referral criteria (AUC 0.59, 95 % CI 0.55-0.63; p < 0.001). On the basis of the thresholds with 90 % (5.6) and 99 % (3.5) sensitivity, we divided the derivation cohort into three risk groups for CRC detection: high (30.9 % of the cohort, positive predictive value [PPV] 40.7 %, 95 % CI 36.7-45.9 %), intermediate (29.5 %, PPV 4.4 %, 95 % CI 2.8-6.8 %) and low (39.5 %, PPV 0.2 %, 95 % CI 0.0-1.1 %). The discriminatory ability was equivalent in the validation cohort (AUC 0.92, 95 % CI 0.90-0.94; p = 0.7). Conclusions: COLONPREDICT is a highly accurate prediction model for CRC detection.
Note: Reproducció del document publicat a:
It is part of: BMC Medicine, 2016, vol. 14, p. 128
Related resource:
ISSN: 1741-7015
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Publicacions de projectes de recerca finançats per la UE

Files in This Item:
File Description SizeFormat 
669601.pdf995.29 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons